FY2027 Earnings Estimate for ENSC Issued By Zacks Research

Ensysce Biosciences, Inc. (NASDAQ:ENSC) – Research analysts at Zacks Research issued their FY2027 earnings estimates for Ensysce Biosciences in a research report issued on Tuesday, March 31st. Zacks Research analyst B. Sorensen forecasts that the company will post earnings of ($0.20) per share for the year. The consensus estimate for Ensysce Biosciences’ current full-year earnings is ($8.33) per share.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ensysce Biosciences in a report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Ensysce Biosciences has a consensus rating of “Sell”.

Ensysce Biosciences Stock Up 4.8%

Shares of NASDAQ:ENSC opened at $0.54 on Wednesday. Ensysce Biosciences has a 52-week low of $0.31 and a 52-week high of $4.85. The stock has a market cap of $1.95 million, a price-to-earnings ratio of -0.13 and a beta of 1.14. The business has a 50-day moving average price of $0.55 and a 200-day moving average price of $1.33.

Ensysce Biosciences (NASDAQ:ENSC) last issued its earnings results on Monday, March 30th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.51. Ensysce Biosciences had a negative return on equity of 458.65% and a negative net margin of 200.87%.The company had revenue of $1.88 million during the quarter, compared to analyst estimates of $0.50 million.

Hedge Funds Weigh In On Ensysce Biosciences

A number of hedge funds have recently bought and sold shares of the business. TRU Independence Asset Management 2 LLC acquired a new stake in Ensysce Biosciences in the third quarter valued at approximately $25,000. Citadel Advisors LLC acquired a new position in shares of Ensysce Biosciences during the 3rd quarter worth approximately $34,000. Virtu Financial LLC purchased a new position in shares of Ensysce Biosciences during the 3rd quarter valued at approximately $34,000. DRW Securities LLC lifted its position in shares of Ensysce Biosciences by 42.4% during the 4th quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock valued at $91,000 after buying an additional 29,336 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. grew its stake in Ensysce Biosciences by 100.4% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock valued at $138,000 after acquiring an additional 75,000 shares during the period. Hedge funds and other institutional investors own 5.63% of the company’s stock.

About Ensysce Biosciences

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.